|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 March 2002, Vol. 99, No. 6, pp. 2265-2267
BRIEF REPORT
Prognostic significance of cellular vascular endothelial growth
factor expression in chronic phase chronic myeloid leukemia
Srdan Verstovsek,
Hagop Kantarjian,
Taghi Manshouri,
Jorge Cortes,
Francis J. Giles,
Anna Rogers, and
Maher Albitar
From the Departments of Leukemia and Hematopathology,
The University of Texas M D Anderson Cancer Center, Houston.
The impact of elevated vascular endothelial growth factor (VEGF)
expression on the course of chronic myeloid leukemia (CML) is unknown.
By radioimmunoassay, we measured pretreatment cellular VEGF protein in
bone marrow samples from 184 (148 chronic and 36 accelerated/blastic
phases) CML patients and found the levels to be 1.6-fold higher than in
31 normal control bone marrow samples (P = .000 01). No
significant differences were found in VEGF levels by different phases
of CML (P = .1). VEGF levels correlated with older age
(P = .01) and higher platelet count
(P = .0003), but also with smaller spleen size
(P = .004), lower white blood cell count
(P = .0006), and lower percentage of peripheral blasts
(P = .04). With the use of Cox proportional hazard model
and VEGF levels as a continuous variable, high VEGF levels correlated
with shorter survival of patients in chronic CML
(P = .008). Multivariate analysis showed that VEGF was
not independent of the synthesis stage (P = .09). These
data suggest that VEGF plays a role in the biology of CML and that VEGF
inhibitors should be investigated in CML.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Loges, G. Heil, M. Bruweleit, V. Schoder, M. Butzal, U. Fischer, U. M. Gehling, G. Schuch, D. K. Hossfeld, and W. Fiedler
Analysis of Concerted Expression of Angiogenic Growth Factors in Acute Myeloid Leukemia: Expression of Angiopoietin-2 Represents an Independent Prognostic Factor for Overall Survival
J. Clin. Oncol.,
February 20, 2005;
23(6):
1109 - 1117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Legros, C. Bourcier, A. Jacquel, F.-X. Mahon, J.-P. Cassuto, P. Auberger, and G. Pages
Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia
Blood,
July 15, 2004;
104(2):
495 - 501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Melani, C. Chiodoni, G. Forni, and M. P. Colombo
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity
Blood,
September 15, 2003;
102(6):
2138 - 2145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rumpel, T. Friedrich, and M. W. N. Deininger
Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase
Blood,
June 1, 2003;
101(11):
4641 - 4643.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Benekli, M. R. Baer, H. Baumann, and M. Wetzler
Signal transducer and activator of transcription proteins in leukemias
Blood,
April 15, 2003;
101(8):
2940 - 2954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cortes, M. Albitar, D. Thomas, F. Giles, R. Kurzrock, A. Thibault, W. Rackoff, C. Koller, S. O'Brien, G. Garcia-Manero, et al.
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
Blood,
March 1, 2003;
101(5):
1692 - 1697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich
Chronic Myelogenous Leukemia
Hematology,
January 1, 2002;
2002(1):
111 - 135.
[Abstract]
[Full Text]
|
|
|
| |
